In a landmark development for pediatric health technology, the US Food and Drug Administration (FDA) has officially cleared Dexcom’s Stelo glucose biosensor system for use in children aged two and older. This decision marks a significant milestone, as Stelo becomes the first over-the-counter (OTC) continuous glucose monitor (CGM) available for pediatric patients, including those managing diabetes. By removing the need for a prescription for this younger demographic, the FDA is signaling a shift toward more accessible, data-driven health management for families navigating both prediabetic conditions and diabetes.
Main Facts: A New Era for Pediatric Glucose Monitoring
The FDA’s clearance expands the indication for Stelo, which was initially authorized for adults aged 18 and older in March 2024. As an integrated CGM (iCGM), Stelo functions as a wearable sensor that synchronizes with a dedicated smartphone application to provide real-time glucose tracking.
Key features of the system include:
- Accessibility: As an OTC device, it bypasses the traditional prescription bottleneck, allowing parents and caregivers to monitor glucose trends without constant physician intervention.
- Duration: Each sensor is designed to be worn for up to 15 days, offering a robust window of data collection before requiring replacement.
- Scope: It is specifically cleared for children two years of age and older who do not use insulin.
This clearance sets Stelo apart from competitors like Abbott’s Lingo and Libre systems, which, as of their June 2024 clearances, remain restricted to adult populations. By capturing the pediatric market, Dexcom has effectively secured a first-mover advantage in the OTC segment for younger users.
Chronology: The Path to Clearance
The journey to this pediatric indication expansion is rooted in the FDA’s evolving regulatory philosophy.
- March 2024: Dexcom receives initial FDA clearance for Stelo, limiting its use to adults aged 18 and over.
- December 2025: The FDA issues a critical guidance document and notification regarding the use of Real-World Evidence (RWE). By removing stringent, legacy limitations on de-identified data in medical device submissions, the agency effectively streamlined the approval pathway for new device indications.
- Early 2026: Dexcom initiates collaborative discussions with the FDA, utilizing a hybrid dataset that combined clinical study data from adult and pediatric diabetes patients with real-world performance data from existing iCGM users.
- Mid-2026: The FDA grants the expanded indication, citing the successful application of RWE as a pillar for the regulatory decision.
Supporting Data: The Power of Real-World Evidence
The approval process for Stelo stands as a case study for the modernization of medical device regulation. Rather than relying solely on prospective, multi-year clinical trials, the FDA utilized RWE to validate the device’s performance across the pediatric age range.
By analyzing de-identified data from existing iCGM users, regulators were able to observe how sensors perform over a 15-day wear cycle in "real-world" conditions—where children are active, attending school, and participating in sports. This evidence-based approach allowed for a faster, more flexible assessment of safety and efficacy compared to traditional methods.
Market Dynamics and Competitive Landscape
According to analysis from GlobalData, the global CGM market is on a rapid growth trajectory, projected to hit a valuation of $15.69 billion by 2035. The competitive landscape remains fierce. As of 2025, Dexcom commanded a 44.7% share of the US CGM market, trailing only slightly behind Abbott, which held a 48.5% share.
While Abbott dominates the international markets—including Europe, the Asia Pacific (APAC) region, and the Middle East and Africa (MEA)—Dexcom’s strategic focus on the pediatric OTC segment in the US may serve as a crucial leverage point to challenge Abbott’s leadership in the coming years.
Official Responses: Fostering Innovation in Pediatric Health
The FDA’s leadership has been vocal about the importance of this clearance, framing it as a triumph for patient-centric care. Michelle Tarver, director of the FDA’s Center for Devices and Radiological Health (CDRH), emphasized the agency’s commitment to pediatric populations.
"Children deserve access to the best tools available to manage their health," Tarver stated. She noted that the clearance reflects the FDA’s broader "commitment to fostering innovation" for younger patients. By enabling the use of Stelo, the agency aims to support the "safe and effective use of medical devices where children live, learn, and play."
Dexcom, in its own communications, has highlighted that the primary goal is to provide peace of mind to caregivers. For parents of children with prediabetes—a condition marked by higher-than-normal blood sugar levels that have not yet reached the threshold for a type 2 diabetes diagnosis—real-time data can be transformative. It allows for dietary and lifestyle adjustments that can significantly alter the long-term health trajectory of a child.
Implications: The Long-Term Impact
The expansion of Stelo into the pediatric market has profound implications for both the healthcare industry and the end-users.
1. Shift Toward Preventive Care
The primary implication is the shift from reactive to proactive care. By making glucose monitoring tools available OTC, the FDA is empowering families to identify glucose spikes early. This is especially vital for the rising number of children diagnosed with prediabetes, providing a "health dashboard" that can encourage healthier habits before a clinical diagnosis of type 2 diabetes occurs.
2. The Normalization of Digital Health
The integration of wearable biosensors into the daily lives of children normalizes the role of digital health. As children become accustomed to monitoring their glucose levels as easily as they check a smartphone, they are likely to develop higher levels of health literacy. This generational shift in technology adoption is expected to decrease the long-term burden on healthcare systems by mitigating complications associated with chronic metabolic conditions.
3. A New Regulatory Standard
The success of the Stelo submission sets a precedent for other medical device manufacturers. The FDA’s willingness to rely on RWE for this approval will likely encourage more companies to pursue similar pathways. This could lead to a wave of pediatric-friendly innovations in other areas of chronic disease management, such as respiratory monitoring or cardiac tracking.
4. Economic Consequences for Healthcare Providers
While the OTC nature of Stelo reduces the administrative burden of prescriptions, it also changes the role of the pediatrician. Physicians will no longer be the gatekeepers of glucose data; instead, they will act as consultants for parents who present them with months of accumulated data from the Stelo app. This transition will require clinicians to become more adept at interpreting patient-generated data and providing actionable advice based on non-clinical settings.
Conclusion
The FDA’s clearance of Dexcom’s Stelo for pediatric use is more than just a regulatory update; it is a fundamental shift in how pediatric health is managed. By combining the convenience of an over-the-counter product with the accuracy of an integrated CGM, Dexcom and the FDA have provided families with a powerful tool for wellness. As the CGM market continues to climb toward its multi-billion dollar valuation, the focus on younger users will undoubtedly remain a key driver of innovation, setting the stage for a future where glucose management is a seamless, data-driven aspect of childhood development.
About the Author
